X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs ALKEM LABORATORIES - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA ALKEM LABORATORIES CIPLA/
ALKEM LABORATORIES
 
P/E (TTM) x 44.2 - - View Chart
P/BV x 3.8 7.4 51.3% View Chart
Dividend Yield % 0.3 0.6 57.8%  

Financials

 CIPLA   ALKEM LABORATORIES
EQUITY SHARE DATA
    CIPLA
Mar-17
ALKEM LABORATORIES
Mar-16
CIPLA/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs6221,589 39.1%   
Low Rs4581,232 37.2%   
Sales per share (Unadj.) Rs181.9417.5 43.6%  
Earnings per share (Unadj.) Rs12.956.3 22.9%  
Cash flow per share (Unadj.) Rs29.364.7 45.3%  
Dividends per share (Unadj.) Rs2.0012.70 15.7%  
Dividend yield (eoy) %0.40.9 41.1%  
Book value per share (Unadj.) Rs155.7292.9 53.1%  
Shares outstanding (eoy) m804.51119.57 672.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.03.4 87.9%   
Avg P/E ratio x42.025.1 167.5%  
P/CF ratio (eoy) x18.421.8 84.5%  
Price / Book Value ratio x3.54.8 72.0%  
Dividend payout %15.522.6 68.9%   
Avg Mkt Cap Rs m434,516168,653 257.6%   
No. of employees `00023.0NA-   
Total wages/salary Rs m26,3389,171 287.2%   
Avg. sales/employee Rs Th6,349.1NM-  
Avg. wages/employee Rs Th1,143.0NM-  
Avg. net profit/employee Rs Th449.3NM-  
INCOME DATA
Net Sales Rs m146,30249,915 293.1%  
Other income Rs m2,2871,645 139.0%   
Total revenues Rs m148,58951,561 288.2%   
Gross profit Rs m24,7588,482 291.9%  
Depreciation Rs m13,2291,006 1,315.3%   
Interest Rs m1,594671 237.7%   
Profit before tax Rs m12,2228,451 144.6%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,7981,606 111.9%   
Profit after tax Rs m10,3546,731 153.8%  
Gross profit margin %16.917.0 99.6%  
Effective tax rate %14.719.0 77.4%   
Net profit margin %7.113.5 52.5%  
BALANCE SHEET DATA
Current assets Rs m87,37027,062 322.9%   
Current liabilities Rs m33,08115,324 215.9%   
Net working cap to sales %37.123.5 157.8%  
Current ratio x2.61.8 149.6%  
Inventory Days Days8767 130.8%  
Debtors Days Days6241 150.9%  
Net fixed assets Rs m111,56712,610 884.8%   
Share capital Rs m1,609239 672.9%   
"Free" reserves Rs m123,64534,490 358.5%   
Net worth Rs m125,25435,027 357.6%   
Long term debt Rs m36,4541,212 3,008.7%   
Total assets Rs m209,53254,387 385.3%  
Interest coverage x8.713.6 63.7%   
Debt to equity ratio x0.30 841.4%  
Sales to assets ratio x0.70.9 76.1%   
Return on assets %5.713.6 41.9%  
Return on equity %8.319.2 43.0%  
Return on capital %8.524.9 34.2%  
Exports to sales %34.212.9 264.3%   
Imports to sales %8.33.1 270.3%   
Exports (fob) Rs m50,0506,461 774.6%   
Imports (cif) Rs m12,2031,540 792.2%   
Fx inflow Rs m51,0666,563 778.1%   
Fx outflow Rs m17,6783,012 587.0%   
Net fx Rs m33,3883,552 940.1%   
CASH FLOW
From Operations Rs m23,8247,259 328.2%  
From Investments Rs m-13,1271,864 -704.1%  
From Financial Activity Rs m-13,239-9,273 142.8%  
Net Cashflow Rs m-2,478-150 1,652.0%  

Share Holding

Indian Promoters % 16.0 66.9 23.9%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 33.1 36.9%  
FIIs % 23.7 0.0 -  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 0.0 -  
Shareholders   161,166 68,381 235.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  ALEMBIC PHARMA  ELDER PHARMA  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Feb 22, 2018 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS